Clinical trial
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects…
NCT00490568 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00490568 |
|---|---|
| Title | Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers |
| Official title | An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Rosiglitazone XR |
| Enrollment | 1,461 |
| Start date | Aug 8, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jun 22, 2007 |
| Last update posted | Nov 13, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Czechia, Finland, France, Germany, Greece and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: